Barclays raised the firm’s price target on Eli Lilly to $630 from $590 and keeps an Overweight rating on the shares post the Q3 report. The company offered supportive commentary on supply, confidence on obesity approval, and absence of concerns on growth outlook “should keep momentum going,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Delivers Robust Q3 Sales Growth
- Eli Lilly cuts FY23 EPS view to $6.50-$6.70 from $9.70-$9.90, consensus $6.72
- Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
- Eli Lilly reports Q3 EPS 10c, consensus (15c)
- Notable companies reporting before tomorrow’s open
